A new blindness drug has come out for Novartis but it is only one of the eight that Dr Daniel Vasella, CEO of Novartis, hopes to be approved this year. CNBC's Ross Westgate reports.
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT